Cambridge Healthtech Institute’s 2nd Annual

Biomarkers for Immuno-Oncology

Enabling the Precise Selection of Immunotherapy for a Better Therapeutic Response

11-12 March 2020

Patient stratification and selection is a crucial step for those developing and providing immunotherapy. However, the heterogeneity of tumours makes it difficult to develop accurate predictive biomarkers for cancer patient populations. Thankfully there is a significant effort across academia and industry to do just this. Combining outputs from genomics, transcriptomics, proteomics and metabolomics, as well as looking into more discreet blood niches, such as circulating tumour cells and exosomes, may indeed provide the answers we need. At Cambridge Healthtech Institute’s 2nd Annual Biomarkers for Immuno-Oncology conference we will address this and more.

Preliminary Agenda

ADDRESSING THE TUMOUR MICROENVIRONMENT

Membrane Hsp70 - A Novel Target for Isolating Circulating Tumour Cells

Graham Pockley, PhD, CEO, multimmune GmbH; Professor of Immunobiology, John van Geest Cancer Research Centre, Nottingham Trent University

Leveraging Novel TCR/Antigen Discovery Technologies For (Pre)Clinical Applications

Wouter Scheper, PhD, Senior Postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute

PREDICTIVE MARKERS AND PRECISION MEDICINE

Opportunities and Challenges for Biomarkers in Early Clinical Development in IO

Bruno Gomes, DVM, PhD, Head of Oncology Biomarkers, Early Clinical Development Oncology, Roche Pharma

Biomarkers of Response to Chemo-Immunotherapy in Metastatic Melanoma

Roxana Dronca, MD, Associate Professor of Oncology, Consultant and Chair, Division of Hematology-Oncology, Mayo Clinic

Quantifying Response and Characterizing Resistance to Neoadjuvant anti-PD1 in Non-Small Cell Lung Carcinoma (NSCLC)

Tricia Cottrell, PhD, Assistant Professor, Immuno-Oncology, Queens University

DIGITAL BIOMARKERS, AI, ML, AND DATA SCIENCE FOR IO

JOINT PRESENTATION: Taking the Pain Out of PD-L1 Scoring - Artificial Intelligence Supported IHC Quantification in Routine Diagnostics

Lukas Heukamp, PhD, Head of Molecular Pathology of Solid Tumors, Institut für Hämatopathologie Hamburg Felix Faber, MSc, CEO, MindPeak

Measuring Performance Status with Digital Tools: A Case Study in Metastatic Solid Tumors

Daniel R. Karlin, MD, MA, CEO, HealthMode, Inc.

Novel Data Science Approaches for the Identification of Multivariate Biomarkers for Simultaneous Diagnosis of Multiple Cancer Diseases

Darius M. Dziuda, PhD, Professor, Mathematical Sciences, Central Connecticut State University

For more details on the conference, please contact:
Joel Hornby, BSc Hons

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-1816
Email: jhornby@healthtech.com

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com